ESR1 and adenocarcinoma: Given that estrogen receptors are expressed in lung tumours, particularly adenocarcinomas, and these cells are responsive to estrogen [32,33], it is possible that hormonal pathways provide an alternative mechanism by which MDM2 influences lung cancer risk in this population.